Accuracy of the Pima™ CD4 Test for Enumeration of CD4+ T-Cell Counts

Abbott RDx Cardiometabolic

Status: Withdrawn

Conditions: AIDS; HIV Infection; HIV Infections

Study type: Observational

Funder types: Other; Industry

Identifiers

NCT00951795

BSTE-0510

Details and patient eligibility

About

This is a multi-center study designed to assess the accuracy of Pima™ CD4 Test to enumerate CD4+ T-cells in whole blood over the measurement range expected for the intended population. The Pima CD4 Test consists of the Pima™ CD4 cartridge and Pima™ Analyzer to identify and determine the absolute counts of mature helper (CD3+/CD4+) T-lymphocytes in whole blood.

Full description

Blood samples will be collected from HIV infected adolescents and adult men and women presenting to a physician's office or outpatient clinic. Capillary whole blood samples will be obtained by fingerstick in duplicate from all Subjects in the study for immediate measurement of CD4+ T-cell count on the Pima CD4 Test by a trained healthcare professional. Venous whole blood samples from all Subjects in the study will also be collected and transported to the clinical laboratory of each study site for concurrent testing on the reference method by a trained laboratory professional. Venous samples from all Subjects in the study will also be measured on the Pima CD4 Test at the study site. Hematocrit will also be measured for all Subjects.

Sex: All

Ages: 12+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

1. 12 years of age or older
2. Confirmed HIV infection, HIV-1 or HIV-2 according to medical history (this inclusion will be waived for healthy non-HIV infected individuals who may need to be enrolled in order to fill the high end of the CD4+ T-cell measurement range of the Pima CD4 Test.
3. Subject agrees to complete all aspects of the study

Exclusion criteria

1. Subject has already participated in this study at a previous date
2. Subject is enrolled in a study to evaluate a new drug
3. Patient unable or unwilling to provide informed consent
4. Vulnerable populations as deemed inappropriate for study by site principal investigator.

Trial design

0 participants in 2 patient groups

Adults

Description:

Adult men and women over age of 18

Pediatrics

Description:

Pediatric boys and girls ages 12-18